Does Ozempic, Wegovy, or Mounjaro Cause Hair Loss? What the Evidence Shows

The rapid adoption of GLP-1 receptor agonists for weight loss has brought a new question into dermatology clinics: is hair shedding a side effect of these medications? The honest, evidence-based answer is that increased shedding is a real and documented experience in a meaningful minority of people taking these drugs, but the mechanism is almost always the same one that causes hair loss after any rapid weight loss or major physiologic stress, rather than a direct toxic effect of the medication on the follicle. This distinction matters because it changes both how the shedding is interpreted and how it is managed. This guide walks through what the trial data actually shows, what mechanism is most likely, and what to expect if you notice your hair coming out in larger amounts than usual.

What the clinical trials reported

Hair loss was specifically tracked as a possible adverse event in the pivotal trials of the GLP-1 and GLP-1 / GIP medications used for weight loss. The published reports are reasonably consistent:

• In the STEP 1 trial of semaglutide (the active ingredient in Ozempic and Wegovy) for chronic weight management, alopecia was reported in 3% of patients on the active drug compared with 1.3% on placebo over 68 weeks (Wilding et al., N Engl J Med, 2021).
• In the SURMOUNT-1 trial of tirzepatide (the active ingredient in Mounjaro and Zepbound), alopecia was reported in 4.9% to 5.7% of patients on the higher doses versus 0.9% on placebo over 72 weeks (Jastreboff et al., N Engl J Med, 2022).
• In liraglutide trials at weight-loss doses, the rate was lower but elevated relative to placebo.

So the signal is real. The interesting feature is that the rate of reported hair loss tracked with the magnitude of weight loss within each trial: patients losing more weight reported more hair loss. That observation is the most useful clue to mechanism.

The mechanism is almost certainly telogen effluvium

The hair growth cycle has three phases: active growth (anagen), a brief transition (catagen), and a 2-to-4 month rest before the hair sheds and a new one begins (telogen). Major physiologic stress, including rapid weight loss, severe caloric restriction, surgery, illness, and childbirth, can synchronously push a large number of follicles from anagen into telogen. Two to three months later, those follicles release their old hairs at the same time. This is called telogen effluvium, and it is the most common reason an otherwise healthy person notices hair coming out in handfuls.

The pattern of GLP-1-related shedding matches telogen effluvium almost perfectly:

• It begins 2 to 4 months after starting the medication or after weight loss accelerates.
• It is diffuse (you lose hair from the whole scalp, not in a pattern) rather than concentrated at the crown or hairline.
• It is self-limited: the shedding phase typically lasts 3 to 6 months and is followed by regrowth that returns density to near baseline.
• It responds to the underlying trigger (the weight loss and the caloric deficit), not to anti-androgen medications.

A fuller explanation of the cycle and what telogen effluvium looks like is in the dedicated stress and hair loss guide. The biology applies directly here.

Why weight loss itself causes shedding

A 10% body weight reduction is biologically a meaningful event. It involves reduced caloric intake, often reduced protein intake, lower iron and ferritin levels in many patients, and shifts in thyroid hormone signaling. Each of these has been independently associated with telogen effluvium in non-GLP-1 contexts: post-bariatric-surgery patients commonly report it, crash dieters commonly report it, and patients recovering from major illness commonly report it. GLP-1 weight loss is producing the same physiologic state as those other triggers, faster than most patients have ever experienced before.

This is also why the rate of shedding tracks with weight loss magnitude. The drugs themselves do not appear to be toxic to follicles in any direct sense; the shedding is a downstream consequence of the physiologic change the drugs enable.

When to suspect something other than telogen effluvium

Most GLP-1-related hair loss is straightforward telogen effluvium. A few patterns suggest a different explanation and are worth flagging to a physician:

• Distinct receding hairline or crown thinning rather than diffuse loss. This pattern is consistent with androgenetic alopecia, which is a separate condition that can run in parallel with, but is not caused by, GLP-1 use.
• Shedding that does not resolve after 6 to 9 months despite stable weight. This is uncommon and warrants evaluation for other causes (thyroid disease, iron deficiency, autoimmune conditions).
• Coin-shaped bald patches rather than diffuse thinning. This pattern suggests alopecia areata, which is unrelated to GLP-1 use.
• Severe scalp itching, redness, or scaling at the same time as shedding. This pattern suggests a scalp condition contributing to the loss.

A dermatologist or telehealth physician can usually distinguish these patterns from history and a scalp exam.

How GLP-1-related shedding is typically managed

The standard approach is reassurance plus optimization, not aggressive intervention. Specifically:

• Adequate protein intake. Hair is structurally protein. Patients in a caloric deficit who are also low on protein are more likely to shed. A practical target is around 0.6 to 0.8 grams of protein per pound of goal body weight, adjusted by your physician for your situation.
• Iron and ferritin assessment. Many weight-loss patients become iron deficient over time, and low ferritin specifically has been associated with chronic telogen effluvium. Ferritin levels below 30 ng/mL in women have been associated with worse hair loss outcomes in observational data (Trost et al., J Am Acad Dermatol, 2006).
• Vitamin D and B12 assessment. Both are commonly low in caloric-restriction states and both have been associated with hair shedding when deficient.
• Time. The most reliable intervention is waiting for the underlying trigger to stabilize. Most telogen effluvium resolves within 6 to 9 months without specific treatment.

A separate guide on supplements covers what the evidence does and doesn't support for general hair loss.

Does it make sense to add minoxidil?

Topical minoxidil can be added to a telogen effluvium episode and may help shorten the shedding phase and improve regrowth density, but it is not the primary treatment. The primary treatment is correcting the underlying trigger. Minoxidil's role in this context is supportive rather than corrective. If you are already on minoxidil for pattern hair loss, you do not need to stop it during a GLP-1-related shedding episode; the medications do not interact.

The dosing and timeline of minoxidil are covered in detail in how minoxidil treats hair loss and how fast does minoxidil work.

What this means if you are deciding about a GLP-1

Hair shedding is one of the smaller adverse effects of GLP-1 therapy, both in absolute rate (a few percent of users) and in severity (usually self-limited and reversible). It is rarely a reason on its own to avoid or stop the medication if the metabolic benefits are meaningful. The honest framing for a patient weighing this is:

• A few percent of users will experience noticeable shedding, typically 2 to 4 months after starting or after weight loss accelerates.
• For the large majority of those, it will be telogen effluvium that resolves within 6 to 9 months as weight loss stabilizes.
• A small fraction may have an underlying pattern hair loss that becomes more visible during the shedding episode and persists after it resolves. That is a separate condition that has its own treatment options.

If you are noticing shedding on a GLP-1 and you also notice the loss is concentrated at the temples or crown rather than diffuse, that is worth a separate conversation about whether pattern hair loss is part of the picture. Curekey's hair assessment is one way to start that conversation with a U.S.-licensed physician.

Related reading

• Stress and hair loss: telogen effluvium: the cycle-based explanation for the most common cause of acute shedding.
• Why hair sheds when you start treatment: a parallel cycle-based explanation for shedding that some treatments themselves can trigger.
• Do hair loss supplements work?: what the evidence supports and doesn't.
• How minoxidil treats hair loss: the most common adjunctive treatment when shedding overlaps with pattern hair loss.
• How it works: what a Curekey assessment and physician review look like.